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Abstract
Background. Despite the increased prenatal diagnosis
of congenital abnormalities of the kidney and urinary
tract (CAKUT), no reliable renal marker for glomerular
ﬁltration rate (GFR) has been validated yet in neonates.
Cystatin C (CysC) is speciﬁc to the neonate and is pro-
posed as a sensitive marker for this population. The aims
of the study were ﬁrst to deﬁne a reference interval in
our center of CysC at birth in normal term babies and
assess CysC as a marker of GFR in a group of term neo-
nates prenatally diagnosed with CAKUT compared to
controls.
Methods. One hundred normal term neonates (control
group) and 33 neonates with kidney malformation (KM)
had the CysC levels in their cord blood measured. A re-
ference interval for CysC in controls was calculated
using non-parametric methods. CysC from controls was
compared ﬁrst to the whole group of neonates with KM,
then with KM group divided in infants (n = 20) with uni-
lateral kidney malformation (UKM) and those (n = 13)
with bilateral kidney malformation (BKM). A multivari-
able analysis was performed to assess the difference in
CysC between the groups with adjustment on other
factors.The ability of CysC to discriminate neonates with
BKM from the controls was assessed by a non-para-
metric receiver-operated characteristics (ROC) curve.
Results. In the control group, the CysC reference inter-
val was [1.54–2.64] mg/L with a median (M) CysC of
2.02 IQR [1.86–2.23]. In the neonates with KM, M
CysC was 1.98 IQR [1.79–2.34]; 1.88 IQR [1.76–2.01]
in the UKM group and 2.52 IQR [2.16–2.71] in BKM
group. Using a multivariate regression analyses, CysC
was signiﬁcantly increased (P < 0.001) in BKM com-
pared to controls with an increment of CysC of 24.5%,
and independent from gender, weight and size. The ROC
curve analyses, comparing BKM versus controls with a
chosen cut-off for CysC of 2.34, showed a sensitivity of
69% and a speciﬁcity of 86%.
Conclusions. Comparing CysC with a reference interval
of CysC validated in our center, we showed a signiﬁcant
increase of CysC in neonates presenting BKM compared
to controls and those with UKM.
Keywords: congenital kidney diseases; cystatin C; neonates; reference
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Introduction
The assessment of renal function in neonates at birth may
be particularly helpful in case of severe congenital
anomalies of the kidney and urinary tract diagnosed
during the prenatal period, not only to identify neonates at
risk to present an abnormal decrease in glomerular ﬁl-
tration rate (GFR) but also to optimize nephrotoxic drugs,
electrolytes and ﬂuids prescriptions in critical situations.
For this population, no accurate renal marker is vali-
dated because the correlation with a gold standard as
clearances implies serial blood samples and timed col-
lected urine, which is challenging in neonates.
Even if plasma creatinine is widely used to evaluate
renal function in children and adults, its measurement is
not speciﬁc for the baby at birth since creatinine crosses
the placenta and is inﬂuenced by the mother’s value for
the 2–3 weeks after birth [1–3]. Cystatin C (CysC) does
not cross the placenta [4, 5] and is proposed as a potential
renal marker for the neonatal period. CysC is a 13 600 Da
protein synthesized by a house-keeping gene in all nu-
cleated cells, which means that its amount in the blood is
constant [6, 7]. In addition, 99% of CysC is freely ﬁltered
through the glomerular membrane without signiﬁcant
peritubular uptake and then completely reabsorbed and
degraded by the proximal tubule. Therefore, urine content
of CysC is negligible and it is not a good candidate for a
urine renal marker [8, 9]. Numerous studies showed that
CysC is independent of gender, age and muscle mass, this
being of particular importance in a paediatric population
[10–12]. CysC can be easily drawn at birth on cord blood
and may provide a rapidly available measure of neonatal
renal function.
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The aims of this study were ﬁrst to validate a reference
interval for CysC in our centre in a large population of
normal term babies without any anomalies detected on
prenatal ultrasound and compare our reference interval for
Cystatin C with those published in the literature [5, 10,
11, 13–15]. Thereafter, we aimed to assess the validity of
CysC levels at birth in neonates prenatally diagnosed with
kidney malformations (KMs), and ﬁnally to compare the
Cystatin C values in this group with the control group of
normal term neonates.
Materials and methods
The protocol (CER 05-111) of this study was approved by the Ethical
committee of Geneva University.
Patients
Since 2008, in the University Maternity of Geneva, term neonates
without any anomalies detected on prenatal ultrasound (n = 100) and
term neonates (n = 33) prenatally diagnosed with kidney anomalies were
included prospectively in the study. In case of kidney dilatation, we con-
sidered for inclusion a measured anterior-posterior diameter of ≥10 mm
during the third trimester of pregnancy. The repartition of the kidneys’
anomalies is described in Table 1.
We recruited the patients during the regular second (26 weeks) or
third (32 weeks) prenatal visit. During this visit, we obtained written
consent to measure CysC by drawing sample on cord blood in the neo-
nates at birth. In the group of normal neonates, babies from mothers pre-
senting complications during pregnancy as diabetes, hypertension and
infection or on medication during pregnancy were not included.
Cystatin C analyses
CysC was measured by particle-enhanced nephelometric immunoassay
(PENIA) on Image®-Beckman analyzer. The assay used for the reaction
is from DakoCytomation. The samples were analysed within 4 h of
being drawn. Samples did not require dilution and results were available
within a few minutes. Only 2 mL of cord blood was required for this
analysis. The coefﬁcient of variation (CV) for CysC (inter-assay pre-
cision) was 4.95% at 1.13 mg/L and 3.30% at 4.91 mg/L (n = 130). The
CV (intra-assay precision) was 2.0% at 1.71 mg/L and 2.3% at 5.37 mg/
L (n = 80). Total measurement uncertainty was 0.097 mg/L at 1.14 mg/L.
Statistical analyses
The distribution of CysC in controls was described by median and inter-
quartile range (IQR) (mg/L). The CysC was log-transformed to fulﬁl the
assumption of a Gaussian distribution. It was tested using a Shapiro–
Wilk’s test. The reference interval (percentiles 2.5 and 97.5%) of the
logarithm of the CysC was assessed by using the non-parametric central
95% conﬁdence interval method and by a robust method following the
Clinical and Laboratory Standards Institute guidelines (CLSI C28-A3)
and back-transformed in the natural scale of the CysC. The conﬁdence
interval of the estimates of CysC reference interval was obtained by
bootstrap (re-sampling 100 00 times). To check the robustness of the es-
timate reference interval for the characteristics of the subjects, it was
assessed in subgroups according to gender, weight and size by using the
robust method.
Characteristics of controls and patients with KM were described (per-
centage or median and IQR) and compared by using a chi-square test (or
a Fisher exact test if some frequencies were <5) and a Mann–Whitney
test. The distribution of the CysC was represented in the groups by box-
plots. The patients with KMs were ﬁrst analysed as the entire group and
compared to controls, then divided in two groups: patients presenting
unilateral KM (UKM) and those with bilateral KM (BKM).
A univariate analysis was performed to test the association between
the CysC value and gender, weight, size, gestational age (GA) and the
different patient groups (controls, unilateral and bilateral malformation).
A multivariate analysis (linear regression) was also performed to
assess the difference in CysC between the groups with adjustment on the
potential confounders (gender, weight and size were signiﬁcant in the
univariate analysis). For this later analysis, the CysC measure was log-
transformed to have a Gaussian distribution. The association between a
factor and CysC (assessed by the regression parameter) was expressed as
a percentage of a variation of the CysC.
The ability of the CysC to discriminate the controls and the patients
with a bilateral malformation was assessed by a non-parametric receiver-
operated characteristics (ROC) curve. The area under the ROC curve and
its 95% conﬁdence interval are reported. The sensitivity and the speci-
ﬁcity were calculated for several cut-off with the 95% conﬁdence inter-
vals obtained by the Clopper–Pearson’s method.
P-values were considered signiﬁcant if <0.05. The statistical analyses
were performed with S-Plus 8.0 (Insightful Corp., Seattle, WA) and
SPSS 15.0 for Windows (SPSS Inc., Chicago, IL).
Results
CysC reference interval
We obtained CysC values in 100 term babies. Fifty-six
were girls (56%). The median for weight was 3.50 kg
IQR [3.23–3.79], for size 51 cm IQR [50–53] and for GA
40 weeks IQR [40–41].
Median cord blood CysC in normal term babies was
2.02 mg/L IQR [1.86–2.23].
The assumption of a Gaussian distribution was rejected
for CysC (P = 0.02) but was adequate for the logarithm of
CysC (P = 0.25). By using the non-parametric central
95% conﬁdence interval method, the reference interval
was [1.61–2.70]. The 95% conﬁdence interval for the as-
sessed low normal value was [1.47–1.67] and [2.52–2.71]
for the high value.
By using the robust method, the reference interval was
[1.54–2.64]. The 95% conﬁdence interval for the assessed
low normal value was [1.47–1.61] and [2.51–2.78] for the
high value. The results from both methods were similar.
When the reference intervals were assessed in sub-
groups according to gender, weight and size, the lower
normal value ranged from 1.49 to 1.63 and the upper
normal value from 2.49 to 2.63.
CysC in neonates with KM
Among the 33 babies (22 boys; 11girls) with KM, 20 had
UKM and 13 had BKM. Neonates with UKM had the fol-
lowing diagnosis: 12 renal pelvic dilatation ≥10 mm, 2
multicystic kidney disease (MCKD), 2 pelvic dysplastic
kidneys, 2 renal agenesis and 2 hypoplastic kidneys.
Among the neonates with BKM, ﬁve patients (pts) pre-
sented with bilateral renal pelvic dilatation ≥10 mm, two
pts with post-urethral valves, two pelvic dilatation ≥10
mm/MCKD, one ectopic dysplastic kidney/MCKD, one
Table 1. Details of the different patient’s congenital kidneys anomaliesa
Diagnosis UKM (pts = 20) BKM (pts = 13)
PDb ≥10 mm 12 5
Post-urethral valves 2
MCKD 2 2/PD and 2/DK
Ectopic dysplastic (pelvic) (DK) 2 1/PD
RA 2 1/DK
Hypoplastic kidney 2
aDK, dysplastic kidney; PD, pelvic dilatation; RA, renal agenesis; pts,
patients.
bMeasure of the anterior-posterior diameter.
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pelvic dilatation ≥10 mm/ectopic dysplastic kidney, one
MCKD/dysplastic kidney (TCF2 mutation) and one
patient renal agenesis/ectopic dysplastic kidney (Table 1).
The control group and the KM group were different in
weight (P < 0.001) and size (P < 0.003) (Table 2), justifying
a multivariate analysis with adjustment on these factors
(Table 3).
CysC in the KM group was not statistically different
from the control group (P = 0.83). The distribution of Cy-
statin C values of each group is illustrated in the box-plot
(Figure 1). The median CysC in each group was: 1.98 IQR
[1.79–2.34] in the KM group, 1.88 IQR [1.76–2.01] in the
UKM group and 2.52 IQR [2.16–2.71] in the BKM group.
The univariate analysis (not shown) yielded similar
results than the multivariate analyses reported in Table 3.
In the multivariate analyses, we conﬁrmed that CysC was
not inﬂuenced by gender and weight. Compared to con-
trols, CysC in the BKM group was signiﬁcantly increased
(P < 0.001) with an augmentation of 24.5%. The UKM
group had lower values of CysC (P = 0.007) but the de-
crease was weak (6.9%).
The ROC curves, analysing BKM versus control,
showed a cut-off for CysC of 2.16, a sensitivity of 76.9%
[46.2; 95.0] and a speciﬁcity of 73.0% [63.2; 81.4]; with
a value of 2.34, a sensitivity of 69.2% [38.6; 90.9] and a
speciﬁcity of 86.0% [77.6; 92.1] and with 2.48, a sensi-
tivity 61.5% [31.6; 86.1] and a speciﬁcity of 92.0% [84.8;
96.5] (Figure 2).
Discussion
Because congenital kidney anomalies represent 30% of
total anomalies diagnosed prenatally [16], the revelation
during pregnancy by ultrasound of a kidney anomaly has
become a frequent reason for nephrology prenatal counsel-
ling. This increase is due principally to technical advances
and a better follow-up of pregnancies. Consequently, the
need to progress in the determination of a useful renal
marker for the neonatal period has become more and more
necessary, not only to improve neonatal care but also to
inform the parents on long-term prognosis. Assessment of
renal function before birth is not accurate and even if the
amount of amniotic ﬂuid is widely used, it is a weak indi-
cator of neonatal renal function and nowadays, none of the
prenatal renal markers proposed have been validated [17–
20]. Bokenkamp et al. proposed that reference values for
CysC in fetal serum could be predictors for renal function,
and obtained by 129 cordocenteses, values in 84 fetuses.
Among these, he deﬁned in a group of 54 fetuses without
kidney disease a mean CysC of 1.66 ± 0.202 mg/L and a
reference interval using parametric method of [1.26–2.06]
mg/L. However, the dosage of serum fetal CysC cannot be
performed routinely because of the risk of fetal loss
associated with fetal blood puncture [4].
The absence of an accurate prenatal marker highlights
the necessity to measure renal function at birth particularly
in neonates presenting bilateral kidney anomalies. Creati-
nine widely used to assess renal function is not useful at
birth to identify neonates susceptible to present renal
failure. Guignard et al. [2, 3] demonstrated that creatinine
rises during the ﬁrst 48 h of life and this increase was even
greater in premature infants. Moreover, creatinine does not
reﬂect the neonates’ value during the ﬁrst 2 weeks of life
[2, 3, 21, 22]. These authors report that the increased crea-
tinine immediately after birth is not only secondary to
mother transfer in the neonate but also to a temporary in-
creased creatinine reabsorption by the kidney attributed to
tubular immaturity of the newborn [2].
It is now recognized that CysC is speciﬁc for the fetus,
implying its use as a potentially valuable renal marker for
neonates [4, 5, 13]. Akbari et al. [23] showed the pro-
gressive rise of Cystatin C in relation with GA in pregnant
women with higher values during the third trimester.
Despite this mother’s CysC increases during pregnancy,
many authors conﬁrmed the lack of correlation between
maternal and fetal CysC [4, 18, 24]. The measure of
CysC in urine and amniotic ﬂuid has been tested in
fetuses with renal obstruction by different authors without
the possibility to establish reference values for CysC in
this condition [17, 24, 25].
CysC reference interval
In the newborn, the validation of a potential renal marker
using a gold standard for GFR is complicated by the need
of repeated blood samples and the difﬁculty to obtain ac-
curate urine collections.
Because of the difﬁculty to compare CysC at this age
with a recognized gold standard, we validated in our
centre a reference interval using the Clinical and Labora-
tory Standards Institute (CLSI C28-A3) guidelines and
calculate reference interval using the robust method as de-
scribed in CLSI guidelines. Two methods are available
and recognized for the measurement of CysC; PENIA and
particle-enhanced turbidimetric immunoassay (PETIA)
[8]. The method used in our centre is PENIA which is
reported to be more sensitive than PETIA [8]. We report
here CysC values in 100 normal term babies and estab-
lished a reference interval for CysC of [1.54–2.64 mg/L]
and the median value for CysC was 2.02 mg/L.
The estimation of the conﬁdence interval for normal
values was similar using both non-parametric and robust
methods and conﬁrmed the robustness of the results ob-
tained with these statistical analyses. In our sample, the
robustness of the CysC reference interval was checked in
the subgroup and showed no clinically meaningful varia-
bility of CysC with gender, weight and size. The literature
reports reference interval for normal term newborns [5,
10, 13–15, 26, 27] and premature [10, 14, 21, 26, 28] at
birth. We compared our results with published data avail-
able for term babies at birth. Bahar et al. [13], reported
lower values than ours, with a mean CysC of 1.36 ± 0.35
mg/L measured by PENIA method, taken from cord
blood in 112 newborns. Treiber et al. measured using the
same methods (PENIA), CysC cord blood value in 75
newborns and found a cord blood value with a mean
CysC value of 1.97 ± 0.36 quite similar to our value of
2.02. Harmoinen et al. analysed 50 full-term infants and
proposed a mean CysC value (PETIA) of 1.70 mg/L ±
2.6 SD and a reference interval of CysC in term babies of
[1.36–2.23] mg/L. Bokenkamp et al. report a mean CysC
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(PETIA) of 2.02 mg/L and a range of 1.64–2.59 mg/L
similar to our results. Barician et al. measured CysC
on Day 1 and Day 3 in 128 neonates, aged from 24 to
≥36 weeks. In the group of term babies (≥36 weeks)
corresponding to our group, 24 neonates had CysC
measured on Day 1 and 21 on Day 3; median CysC was
1.84 mg/dL and the reference interval of [1.32–2.63].
Using a regression analysis, the authors showed no sig-
niﬁcant correlation between GA and CysC on Day 3,
whereas there was a weak, but signiﬁcant, positive corre-
lation on Day 1 (r = 0.275, P = 0.0037); however, they
analysed a population with different GA. In our popu-
lation, we did not observe a relationship with GA, most
likely because our infants had a GA >36 weeks [29].
Numerous studies evaluated the interest of CysC to
predict GFR in adult and in older children and found a
good correlation with a recognized gold standard [6, 10,
15, 30, 31]. Only a few have studied the correlation of
CysC with a gold standard in neonates. This was done by
Montini et al. who measured GFR in 20 premature neo-
nates (28–34 weeks of gestation) using single-shot inulin
clearance where inulin was injected through a central
catheter previously inserted for clinical reason. Then the
authors compared CysC and creatinine GFR obtained
with inulin clearance; infants with a GFR <0.5 mL/min/
1.73 m2 had CysC >2 mg/L and inversely premature with
normal clearance >0.5 mL/min/1.73 m2 had CysC <2 mg/
L [13]. Different CysC-based formulas to derive GFR
from CysC were described but none have been validated
yet for neonates [4, 31].
CysC in neonates with prenatal diagnosis of KM
To assess the validity of CysC at birth in neonates with
congenital renal anomalies, we compared the group pre-
senting malformation of the kidneys with the group of
Fig. 1. Box-plot: median (M) and IQR. CysC in the different groups: M
CysC in controls was 2.02 IQR [1.86–2.23] mg/L, 1.98 IQR [1.79–2.34]
in KM, 1.88 IQR [1.76–2.01] in UKM and 2.52 IQR [2.16–2.71] in
BKM.
Fig. 2. ROC-curve BKM versus controls: with a CysC cut-off of 2.34
mg/L, the calculate sensitivity was 69.2% and speciﬁcity 86.0%. With a
cut-off of 2.48, the calculate sensitivity was 61.5% and speciﬁcity
93.3%. Area under curve = 0.777 [0.599–0.955].
Table 2. Descriptive analysis: patients characteristics; median [IQR] for gender, weight and sizea
Control KM UKM BKM P
Gender, N (%)
Girls 56 (56) 11 (33) 7 (35) 4 (30) 0.08
Boys 44 (44) 22 (66) 13 (650) 9 (69)
Weight (kg), median [IQR] 3.50 [3.23–3.79] 3.16 [2.90–3.43] 3.05 [2.86–3.21] 3.39 [3.17–3.57] <0.001
Size (cm), median [IQR] 51 [50–53] 50 [48–51] 50 [48–51] 50 [49–51] 0.003
aP-value compared three groups: control, UKM and BKM.
Table 3. Multivariate regression analysis on the CysC including gender,
size, control group, patients with UKM and BKM as potential
predictorsa
Multivariate
Estimates SEb P-value CysC increase (%)
Gender
Girls
Boys 0.039 0.026 0.13 3.8
Weight (per kg) −0.052 0.037 0.16 −2.8
Size (per cm) 0.002 0.009 0.84 −0.5
Group
Control
UKM −0.103 0.038 0.007 −6.9
BKM 0.178 0.04 <0.001 24.5
aUKM had a signiﬁcant decrease of 6.9% (P = 0.007) and BKM a
signiﬁcant increase of 24.5% (P < 0.001).
bstandard error.
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normal term babies. The multivariate analyses conﬁrmed
that CysC was not inﬂuenced by gender, weight and size
and both groups were comparable.
We observed that the median CysC for the entire group
of KM was 1.98 mg/L and not statistically different from
the control group 2.02 mg/L. When analysing separately
neonates presenting UKM or BKM, interestingly, we found
in neonates with BKM, a signiﬁcantly increased mean
CysC compared to the control group (P < 0.001) with a
CysC increment of 24.5%. In our population, a high level
of CysC in neonates with BKM may reﬂect the low renal
endowment in these neonates. In normal term babies, the
nephron mass is complete at birth. However, impaired
kidney development occurs in neonates with congenital
kidney anomalies leading likely to a lower number of ne-
phrons at birth and an increased risk to present lower renal
function at birth [32–35]. Compensatory mechanisms such
as hyperﬁltration of the residual nephrons will take place
later in these infants leading to a pre-disposition to future
hypertension and renal insufﬁciency [35, 36].
Surprisingly, mean CysC in neonates with UKM was
signiﬁcantly lower from the control group. One of the
explanations could be the lower weight of the neonates in
this group, but the multivariate analyses showed no
impact of weight on CysC values. Another reason may be
the small sample size of this group (n = 20). We hypoth-
esize that this decrease in CysC could be secondary to
hyperﬁltration of the nephrons of the opposite normal
kidney. To analyse this hypothesis, we calculate the
length of the kidneys to seek for a possible hypertrophic
growth of the normal opposite kidney with sizes reported
as z-score for length (results not shown). The difference
was not signiﬁcant, probably biased by the fact that the
principal kidney anomaly in this group was pelvic dilated
kidney with an increased size.
Finally, we were interested to propose a cut-off CysC
value that may be used as an indicator of an increased
risk to present reduced renal function at birth; we used
ROC curve analyses and compared neonates with BKM
versus controls. With a chosen cut-off of 2.34 mg/L, the
sensitivity to present a bilateral anomaly was 69% with a
high speciﬁcity of 86%. This value may discriminate in
case of kidney anomalies neonates with lower renal func-
tion at birth. However, the sample size was not sufﬁcient
to validate this cut-off.
In conclusion, CysC values in neonates presenting a
unilateral kidney anomaly were similar to controls
whereas CysC was signiﬁcantly increased in infants pre-
senting a bilateral kidney anomaly. Although we are
aware that the validity of CysC in neonates will not be
complete without a correlation with a gold standard, CysC
may be a useful marker, readily available at birth on cord
blood in neonates prenatally diagnosed with congenital
renal diseases, to identify those susceptible to present de-
creased renal function.
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Abstract
Background. Unrecognized myocardial infarctions
(UMIs) are common in the general population but have
not been well studied in patients with chronic kidney
disease (CKD). The purpose of this study was to deter-
mine the prevalence and prognosis for mortality of UMI
among adults with CKD.
Methods. The current study included 18 864 participants
in the population-based REasons for Geographic And
Racial Differences in Stroke (REGARDS) study who com-
pleted a baseline examination including a 12-lead electro-
cardiogram (ECG). UMI was deﬁned as the presence of
myocardial infarction (MI) by Minnesota ECG classiﬁ-
cation in the absence of self-reported or recognized MI
(RMI). Estimated glomerular ﬁltration rate (eGFR) was cal-
culated using the Chronic Kidney Disease Epidemiology
Collaboration equation and albuminuria using albumin-to-
creatinine ratio from a spot urine sample. All-cause
mortality was assessed over a median 4 years of follow-up.
Results. The prevalence of UMI was 4, 6, 6 and 13%
among participants with eGFR levels of ≥60, 45–59.9, 30–
44.9 and <30 mL/min/1.73m2, respectively, and 4, 5, 7 and
10% among participants with albuminuria levels of <10,
10–29.9, 30–299.9 and ≥300 mg/g, respectively. Compared
to those with no MI, the multivariable adjusted hazard ratio
for all-cause mortality associated with UMI and RMI was
1.65 [95% conﬁdence interval (CI): 1.09–2.49] and 1.65
(95% CI: 1.20–2.26), respectively, among individuals with
an eGFR <60 mL/min/1.73m2 and 1.49 (95% CI: 1.03–
2.16) and 1.88 (95% CI: 1.40–2.52) among individuals
with albuminuria ≥30 mg/g.
Conclusion. UMIs are common among individuals with
an eGFR <60 mL/min/1.73m2 and albuminuria and associ-
ated with an increased mortality risk.
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